decreas
germin
center
format
lymph
node
product
nonprotect
antibodi
antibodi
fail
neutral
rsv
allow
replic
secondari
stimul
rsvprime
cell
produc
lowavid
antibodi
result
immun
complex
deposit
affect
tissu
howev
formalininactiv
rsv
administ
tlr
agonist
mice
protect
wildtyp
viru
challeng
safe
effect
vaccin
rsvmeasl
viru
dengu
viru
may
benefit
better
understand
innat
immun
respons
promot
product
protect
antibodi
past
decad
differ
line
scientif
inquiri
contribut
improv
understand
antibodymedi
mechan
control
sever
diseas
accompani
heterotyp
viral
infect
follow
incomplet
immun
case
heterotyp
infect
independ
studi
cellular
host
respons
acut
chronic
human
anim
viral
diseas
provid
evid
link
immun
complex
receptor
enhanc
infect
sever
mechan
term
intrins
antibodydepend
enhanc
iad
parallel
studi
immun
respiratori
syncyti
viru
rsv
antigen
demonstr
use
formalininactiv
viral
immunogen
yield
defici
tolllik
receptor
tlr
activ
b
cell
defect
affin
matur
nonprotect
antibodi
sever
wildtyp
viral
diseas
occur
presenc
antibodi
character
eosinophilia
complement
fixat
arthuslik
phenomena
research
histori
two
innat
immun
responsetrigg
antibodymedi
viral
immunopatholog
review
iad
hawk
observ
enhanc
plaqu
format
murray
valley
enceph
viru
mvev
incub
low
concentr
antibodi
studi
neutral
use
serumdilut
virusconst
method
greater
number
plaqu
observ
chicken
embryo
fibroblast
monolay
contain
high
dilut
chicken
mvev
antisera
virusonli
control
studi
suggest
plaqu
enhanc
result
stabil
infect
virusantibodi
complex
subneutr
antibodyviru
complex
infect
monocytesmacrophag
subsequ
describ
patholog
mechan
secondari
dengu
viru
denv
infect
explain
observ
sequenti
denv
infect
result
sever
diseas
led
recognit
chicken
embryo
fibroblast
monolay
contain
function
macrophag
support
mvev
infect
plaqu
format
presenc
chicken
mvev
antibodi
importantli
system
requir
phylogen
class
donor
igg
antibodi
donor
cell
initi
studi
ade
assum
increas
viru
output
case
approach
result
avid
attach
immun
complex
iia
receptor
respect
therefor
yield
larger
number
cell
infect
presenc
absenc
antibodi
exampl
mous
macrophagelik
cell
signific
increas
attach
west
nile
viru
immun
complex
compar
nake
viru
particl
observ
use
felin
infecti
periton
fip
viru
fipv
increas
number
periton
macrophag
infect
vitro
presenc
absenc
antibodi
also
possibl
immun
complex
intern
rapidli
nake
viru
observ
human
immunodefici
viru
hiv
type
model
mechanist
concept
ade
chang
radic
result
studi
macrophag
infect
ross
river
viru
rrv
immun
complex
human
acut
infect
rrv
often
evolv
postinfect
arthriti
mani
month
durat
sampl
arthriti
patient
synovi
cell
stain
rrv
antigen
synovi
fluid
contain
gamma
interferon
attempt
model
phenomenon
chronic
rrv
infect
establish
mous
macrophag
cell
line
confirm
primari
human
monocytesmacrophag
remark
incub
rrv
dilut
rrv
antiserum
result
enhanc
infect
cell
complex
phenomenon
involv
increas
product
viru
result
immun
complex
suppress
innat
cellular
immun
innat
immun
suppress
involv
decreas
product
reactiv
nitrogen
radic
via
nitric
oxid
synthas
suppress
downregul
tumor
necrosi
factor
alpha
product
abolish
interferon
regulatori
factor
nuclear
factorb
gene
express
mark
increas
gene
transcript
protein
product
observ
critic
suppress
phenomenon
requir
infecti
immun
complex
sinc
ligat
zymosanantibodi
complex
presenc
rrv
ablat
antivir
transcript
thu
rather
simpli
evok
increas
number
infect
cell
rrv
ade
complex
phenomenon
involv
increas
product
viru
result
immun
complex
suppress
innat
cellular
immun
ade
phenomenon
attract
wide
interest
virolog
mani
virus
replic
macrophag
vivo
manifest
enhanc
infectionsdiseas
antibodyenhanc
infect
requir
initi
immunolog
event
term
sensit
occur
three
set
primari
infect
natur
occur
heterotyp
virus
genera
group
ii
infect
virus
creat
antigen
divers
rapid
evolut
biolog
antigen
variant
cours
chronic
infect
group
iii
immun
result
incomplet
protect
immun
group
virus
group
includ
four
dengu
virus
group
includ
lactic
dehydrogenas
viru
fipv
porcin
reproduct
respiratori
syndrom
prr
viru
simian
hemorrhag
fever
shf
viru
hiv
equin
infecti
anemia
eia
viru
caprin
arthriti
ca
viru
african
swine
fever
viru
use
review
avail
group
dengu
virus
human
sever
dengu
viru
infect
follow
stereotyp
cours
outcom
anoxia
shock
gastrointestin
hemorrhag
accompani
rapid
loss
fluid
vascular
compart
due
capillari
permeabl
occur
around
time
defervesc
studi
pathogen
mechan
consider
effort
direct
measur
blood
cytokin
level
patient
late
acut
phase
dengu
ill
prior
onset
shock
high
level
proinflammatori
immunomodulatori
cytokin
includ
associ
sever
diseas
indirect
evid
suggest
cytokin
mediat
dengu
viru
vascular
permeabl
infectionenhanc
antibodi
risk
factor
enhanc
dengu
diseas
enhanc
viremia
shown
anticipatori
correl
sever
diseas
recent
patholog
studi
human
tissu
firmli
establish
central
role
monocyt
macrophag
immatur
matur
dendrit
cell
infect
target
cell
correl
studi
valid
vitro
use
variou
human
primari
continu
monocyt
macrophag
cell
line
surrog
model
vivo
infect
vitro
ade
infect
cell
model
human
monocyt
receptorbear
continu
cell
line
intracellular
denv
product
increas
result
idiosyncrat
receptor
signal
immun
complex
ligat
least
two
type
suppress
pathway
express
deoxyadenosin
kinas
dak
antigen
autophagyrel
gene
complex
sarm
steril
alphaand
armadillomotifcontain
protein
tank
traf
famili
memberassoci
nfb
activ
pathway
plu
posit
cytokin
regul
pathway
fig
collect
downregul
antivir
respons
adeinfect
target
cell
dak
complex
retinoid
acidinduc
gene
imelanoma
differentiationassoci
gene
abolish
express
weaken
signal
pathway
monitor
level
downstream
signal
molecul
beta
interferon
promot
stimul
induc
ib
kinas
ikki
tumor
necrosi
factor
receptorassoci
factor
tankbind
kinas
tbki
etc
outcom
decreas
product
type
ifn
well
interferonactiv
antivir
molecul
activ
sarm
tank
result
express
blockag
tlr
inhibit
myeloid
differenti
primari
respons
gene
depend
signal
pathway
result
anoth
rout
type
ifn
suppress
result
least
two
suppress
pathway
adeinfect
cell
secret
reduc
level
type
ifn
time
suppress
transcript
translat
facilit
express
synthesi
antiinflammatori
cytokin
ade
infect
also
suppress
innat
antidenv
mediat
nitric
oxid
radic
disrupt
transcript
induc
nitric
oxid
synthas
ino
gene
transcript
factor
suppress
mode
believ
mediat
activ
synthes
earli
phase
ade
infect
cell
experiment
set
induc
bias
also
oper
via
suppressor
cytokin
signal
soc
system
suppress
janu
kinasesign
transduc
activ
transcript
jak
stat
signal
pathway
result
suppress
ino
gene
express
reduct
nitric
oxid
radic
product
viral
enhanc
effect
abolish
small
interf
rna
specif
gene
conclud
vitro
iad
infect
facilit
viral
entri
also
modifi
innat
adapt
intracellular
antivir
mechan
result
enhanc
denv
replic
fig
critic
respons
observ
vivo
genomewid
transcriptom
peripher
blood
mononuclear
cell
pbmc
collect
acut
phase
children
dengu
fever
df
dengu
hemorrhag
fever
dhf
compar
use
microarray
analysi
patient
dhf
decreas
level
reduc
ifn
transcript
pbmc
increas
blood
level
compar
patient
milder
ill
ifn
gene
upregul
product
significantli
elev
patient
mild
dengu
ill
compar
patient
sever
dengu
ill
studi
acut
stage
sever
diseas
increas
product
downregul
multipl
ifn
regulatori
gene
note
protect
role
ifn
moder
dengu
viru
infect
clearli
demonstr
mous
model
suggest
human
df
precis
role
immun
complexelicit
product
clinic
evolut
sever
dengu
viru
infect
well
understood
may
respons
observ
shift
dhf
howev
ade
infect
primari
monocyt
synthesi
peak
serum
dilut
produc
peak
viru
yield
marovich
person
commun
addit
point
mutat
promot
posit
ag
ct
ca
result
polymorph
differenti
monocyt
high
intermedi
low
produc
respect
phenotyp
correl
diseas
sever
requir
investig
studi
vitro
respons
human
myeloid
cell
iad
infect
differ
human
monocyt
activ
macrophag
matur
dendrit
cell
dc
support
ade
immatur
dc
infect
macrophag
denv
type
alon
fulli
neutral
immun
complex
stimul
high
level
downmodul
ade
condit
replac
secret
type
ifn
produc
infect
monocyt
observ
human
dengu
ill
need
better
understand
iad
phenomenon
context
understand
dhf
infant
accompani
primari
denv
viru
infect
acquir
latter
half
first
year
life
import
attract
recent
research
interest
uniqu
clinic
phenomenon
illustr
role
play
dengu
viru
antibodi
modul
diseas
express
also
bifurc
role
protect
birth
high
concentr
enhanc
month
later
subneutr
concentr
contribut
immatur
denv
particl
iad
interest
immatur
dengu
virion
infecti
human
myeloid
cell
presenc
enhanc
dengu
antibodi
ade
infect
occur
readili
surmis
immatur
denv
fig
twoloop
model
iad
ligat
infecti
denvsubneutr
antibodi
complex
induc
suppress
innat
immun
respons
upregul
neg
regul
pathogen
pattern
recognit
dak
sarm
tank
subsequ
abolish
express
rlr
tlr
signal
pathway
result
decreas
type
interferon
proinflammatori
cytokin
product
serv
suppress
interferonmedi
antivir
respons
ii
earli
activ
potent
activ
soc
system
suppress
jakstat
signal
pathway
turn
interferonsign
pathway
known
promot
type
cytokin
respons
result
cytokin
bias
two
loop
suppress
switch
intracellular
antivir
respons
denvinfect
cell
iad
condit
result
product
high
number
infecti
virion
tyrosin
kinas
isr
interferonstimul
respons
element
oa
synthas
pkr
protein
kinas
r
isg
interferonstimul
gene
ga
gamma
interferonactiv
sequenc
prostaglandin
e
vol
minireview
march
guest
http
cviasmorg
releas
circul
human
infect
antibodi
prm
immatur
denv
antigen
frequent
observ
ii
group
ii
iii
fip
describ
briefli
exampl
group
ii
iii
viru
immunopatholog
involv
ade
felin
coronavirus
exist
two
form
first
form
felin
enter
coronaviru
fecv
pathogen
minor
signific
spontan
mutat
viru
result
second
form
fipv
replic
periton
macrophag
produc
periton
occasion
fip
fatal
arthuslik
pyogranulomat
diseas
kitten
cat
ade
incrimin
diseaseenhanc
factor
antibodi
pathogen
evidenc
observ
kitten
acquir
passiv
matern
fipv
antibodi
develop
rapid
fulmin
diseas
follow
challeng
fipv
seroneg
kitten
diseas
enhanc
demonstr
cat
infect
presenc
vaccinederiv
humor
immun
direct
spike
protein
fipv
similarli
cat
immun
recombin
vaccinia
viru
express
spike
protein
fipv
die
earlier
control
anim
adult
cat
fipv
develop
chronic
infect
felin
coronavirus
fecv
mutat
fipv
gain
macrophag
tropism
antibodi
respons
fipv
mount
infect
diseas
sever
enhanc
summari
antibodi
respons
fipv
occur
cours
infect
passiv
transfer
antibodi
natur
infect
immun
kill
recombin
vaccin
led
enhanc
fipv
diseas
enhanc
diseas
sever
attribut
larg
gener
nonneutr
antibodi
defect
activ
tlr
human
sever
diseas
syndrom
accompani
reinfect
follow
administr
kill
measl
viru
rsv
vaccin
recogn
antibodydepend
immunopatholog
phenomena
distinct
phenomenon
dengu
virus
respons
larger
group
viral
diseas
sensit
sever
outcom
result
human
intervent
usual
immun
use
inactiv
viral
antigen
basi
publish
descript
report
addit
rsv
measl
viru
viru
diseas
enhanc
follow
immun
includ
caus
human
metapneumoviru
hmpv
influenza
viru
rabi
viru
shf
viru
fipv
prr
viru
hiv
eia
viru
ca
viru
aleutian
diseas
mink
ad
viru
describ
recent
discov
mechan
control
diseas
enhanc
rsv
known
diseas
list
may
modifi
iad
may
modifi
defect
activ
tlr
measl
respiratori
syncyti
viru
postvaccin
infect
syndrom
formaldehyd
wide
use
manufactur
mani
safe
commerci
vaccin
formaldehydeinactiv
fi
rsv
firsv
measl
viru
vaccin
caus
disastr
worsen
diseas
subsequ
natur
infect
phenomenon
accompani
dissoci
neutral
glycoprotein
antibodi
respons
enhanc
respons
tissu
eosinophilia
dengu
model
tcell
respons
rsv
infect
part
effer
immun
respons
contribut
tissu
patholog
identifi
cellular
infect
well
establish
cell
signal
host
attempt
contain
elimin
virusinfect
cell
role
cell
rsv
lung
patholog
follow
administr
kill
vaccin
suspect
establish
firsvspecif
antibodi
absenc
cell
suffici
caus
diseas
enhanc
interest
challeng
wildtyp
hmpv
cynomolgu
monkey
vaccin
formalininactiv
hmpv
member
rsv
famili
caus
similar
respiratori
syndrom
human
develop
clinic
patholog
respons
suggest
enhanc
immunemedi
diseas
initi
one
lead
hypothesi
firsv
patholog
exampl
ade
bonnet
monkey
model
antibodi
increas
viru
infect
pulmonari
macrophag
howev
vivo
pulmonari
epitheli
cell
macrophag
prime
target
infect
also
observ
fi
antibodi
enhanc
rsv
measl
viru
diseas
anim
model
form
infecti
immun
complex
activ
complement
patholog
respons
affect
lung
function
may
also
possibl
reflect
differenti
postul
formaldehydeinactiv
protein
rais
antibodi
reduc
protect
capac
increas
number
reactiv
carbonyl
group
favor
immun
respons
follow
phagocytosi
macrophag
via
scaveng
receptor
howev
inactiv
rsv
method
use
formalin
also
sensit
experiment
anim
enhanc
diseas
mice
immun
rsv
treat
uv
radiat
purifi
fusion
f
protein
vaccinia
viru
rsv
replic
construct
experienc
enhanc
diseas
follow
challeng
wildtyp
viru
highand
lowavid
antibodi
direct
amino
acid
epitop
f
protein
amino
acid
recent
shown
test
mice
formalin
inactiv
deconform
epitop
result
failur
avid
matur
character
suboptim
matur
dendrit
cell
reduc
product
activ
factor
decreas
germin
center
format
lymph
node
lowavid
antibodi
respons
uv
radiationtr
f
protein
could
convert
high
avid
administ
antigen
five
consecut
day
determin
tlr
activ
requir
avid
matur
downstream
adaptor
tlr
includ
present
inocul
wildtyp
rsv
result
avid
protect
antibodi
respons
mice
inocul
immunogen
protect
passiv
cellular
transfer
experi
use
mice
reveal
tlr
stimul
occur
b
lymphocyt
interest
uv
radiationinactiv
viru
administ
along
tlr
agonist
lipopolysaccharid
agonist
poli
c
plu
poli
u
agonist
oppos
use
alum
tlrindepend
adjuv
mice
protect
rsv
challeng
summari
poor
tlr
stimul
inactiv
rsv
vaccin
associ
lack
matur
led
product
nonprotect
antibodi
antibodi
essenti
pathogenesi
enhanc
diseas
fail
neutral
wildtyp
rsv
minireview
clin
vaccin
immunol
march
guest
http
cviasmorg
allow
unrestrict
replic
secondari
stimul
rsvprime
cell
lowavid
antibodi
contribut
diseas
sever
immun
complex
format
deposit
affect
tissu
somewhat
similar
observ
made
worker
coadminist
agonist
cpg
formalininactiv
rsv
vaccin
observ
protect
effect
agonist
coadministr
compar
effect
control
discuss
review
describ
antibodi
oper
earli
stage
infect
direct
virus
target
cell
dengu
viru
modifi
antigen
present
form
nonneutr
antibodi
rsv
critic
differ
antibodymedi
outcom
differ
princip
host
cell
support
infect
two
diseas
mononuclear
phagocyt
target
cell
diseas
initi
ade
rsv
measl
viru
like
parenchym
lung
epitheli
cell
support
infect
limit
involv
mononuclear
phagocyt
two
rather
differ
exampl
antibodydepend
viral
immunopatholog
unifi
interact
innat
immun
system
innat
immun
respons
viral
target
antigenpres
cell
modifi
imped
potenti
benefici
respons
accompani
follow
human
infect
vaccin
focu
review
interpret
undermin
import
cell
contribut
protect
patholog
respons
infect
cours
elimin
virusinfect
cell
case
diseas
iad
group
evid
dengu
research
suggest
innat
immun
respons
engin
increas
product
viru
presum
diseas
sever
direct
correl
infect
sever
case
rsv
defect
activ
tlr
antigenpres
cell
result
product
nonneutr
pathogen
antibodi
find
describ
modifi
previou
measl
viru
rsv
paradigm
ascrib
atyp
diseas
poor
antibodi
function
due
formalin
disrupt
protect
epitop
present
formalininactiv
rsv
measl
viral
antigen
result
immunogen
fail
stimul
result
failur
affin
matur
nonavid
nonneutr
complementfix
antibodi
rais
administr
formalininactiv
vaccin
interact
produc
patholog
immun
complex
wildtyp
viral
infect
start
respiratori
tract
antibodi
essenti
pathogenesi
enhanc
diseas
fail
neutral
rsv
permit
replic
secondari
stimul
rsvprime
cell
import
progress
made
identifi
role
innat
immun
success
live
attenu
viral
vaccin
singl
inject
induc
cytotox
lymphocyt
mix
profil
neutral
antibodi
persist
year
respons
depend
upon
fundament
role
innat
immun
system
particularli
tlr
antigenpres
cell
dc
infect
dc
signal
multipl
tlr
distinct
subset
dc
comput
analys
identifi
gene
signatur
includ
complement
protein
eukaryot
translat
ignit
factor
alpha
kinas
correl
tcell
respons
bcell
growth
factor
contribut
protect
neutral
antibodi
respons
import
note
mani
viral
diseas
formalininactiv
antigen
produc
highli
efficaci
vaccin
japanes
enceph
poliomyel
exampl
mechan
protect
influenza
formalininactiv
antigen
less
clear
work
cite
suggest
safe
effect
rsv
vaccin
infant
may
feasibl
administ
vaccin
tlr
agonist
rais
neutral
antibodi
achiev
protect
efficaci
similar
elicit
live
viru
inocul
may
special
reson
develop
tetraval
dengu
vaccin
deriv
live
attenu
vaccin
provid
tetraval
immun
follow
singl
dose
prove
difficult
role
iad
larg
group
predominantli
veterinari
macrophagetrop
viral
pathogen
group
ii
iii
yet
firmli
establish
use
vaccin
compos
care
character
inactiv
subunit
antigen
select
adjuv
may
result
balanc
protect
immun
respons
answer
may
lie
better
understand
use
innat
immun
